Exjade Novartis - Treatment for Chronic Iron Overload Due to Blood Transfusions
Exjade is a once-daily oral iron chelator approved for the treatment of chronic iron overload due to blood transfusions in adults and children age two and older.Posted: November 2005
Related Articles:
- FDA Approves Exjade to Remove Excess Iron in Patients with Genetic Blood Disorder - January 23, 2013
- FDA Advisory Committee Votes Unanimously to Recommend Approval of Exjade for Once-Daily Oral Treatment of Chronic Iron Overload Due to Blood Transfusions - September 29, 2005
- FDA Grants Priority Review for Exjade for the Treatment of Chronic Iron Overload Due to Blood Transfusions - June 22, 2005
- Novartis Files Exjade New Drug Applications for Treatment of Chronic Iron Overload Due to Blood Transfusions - May 3, 2005
